Category: Latest News
-

YYForce Secures UAE Hospitality Staffing Contracts as Middle East Operations Expand
YYForce Inc. (NASDAQ:YFOR), a provider of AI-enabled workforce and facility management solutions, announced on Friday that it has secured new hospitality staffing contracts in the United Arab Emirates as part of its expansion across the Middle East. The Singapore-based company said it has completed group-level vendor registration and begun deploying personnel at luxury hospitality properties…
-

US Producer Prices Rise 0.3% in October, Below Expectations, as Annual Inflation Reaches 6.5%
US producer prices increased less than economists had anticipated in October, although the annual rate of wholesale inflation accelerated to its highest level in nearly four years, according to figures released by the Department of Labor on Friday. The producer price index (PPI) for final demand rose 0.3% month over month in October, following an…
-

Wall Street Futures Rise as Nvidia Rebounds and US Producer Price Inflation Comes in Below Forecasts: Dow Jones, S&P, Nasdaq
US stock index futures pointed to a higher opening on Friday as investors assessed a recovery in Nvidia shares and producer price inflation data that came in slightly below economists’ expectations. The anticipated gains followed a session in which major Wall Street indices recovered from their intraday lows but nevertheless finished in negative territory. Technology…
-

Roche Receives Positive EU Committee Recommendation for Gazyva/Gazyvaro in Systemic Lupus Erythematosus
Roche (USOTC:RHHBY) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gazyva/Gazyvaro (obinutuzumab) as an additional treatment for adults with moderate-to-severe, active, autoantibody-positive systemic lupus erythematosus (SLE) whose disease remains active despite standard therapy. The recommendation represents a regulatory step toward potential European Union…
-

Novo Nordisk Submits Sickle Cell Disease Treatment Etavopivat for US and European Regulatory Approval
Novo Nordisk (NYSE:NVO) has submitted regulatory applications in the United States and Europe seeking approval for etavopivat, an investigational oral treatment for sickle cell disease in patients aged 12 years and older. The pharmaceutical company filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA)…
-

Why Is Prairie Operating Stock Surging 10% Despite Missing Earnings Estimates?
Prairie Operating Co. (NASDAQ:PROP) shares advanced 10.48% in US premarket trading on Friday after the oil and gas producer reported third-quarter 2026 revenue that exceeded analysts’ expectations, supported by higher production volumes and increased output from newly completed wells. The company reported revenue of $129.5 million, approximately 34% above the consensus estimate of $96.87 million.…
-

Why Is Snail Stock Surging 20% Following Its Third-Quarter Results?
Snail, Inc. (NASDAQ:SNAL) shares advanced 20.19% in US premarket trading on Friday after the video game publisher reported third-quarter 2026 financial results showing a substantial increase in revenue, higher game sales and a return to net profitability. The company reported revenue of $33.1 million, representing a 139.2% increase compared with the corresponding period of 2025.…
-

Why Is SBC Medical Stock Surging 12% Following Its Third-Quarter Results?
SBC Medical Group Holdings Incorporated (NASDAQ:SBC) shares advanced 12.36% on Friday after the medical services company reported third-quarter 2026 earnings and revenue that exceeded analysts’ expectations, supported by revised service fees, the consolidation of Waqoo and continued expansion of its clinic network. The company reported a 35% year-over-year increase in revenue to $58.58 million, alongside…
-

Why Is Immunic Stock Falling 5% Following Its Third-Quarter Results?
Immunic Inc. (NASDAQ:IMUX) shares declined 5.44% in US premarket trading on Friday after the biotechnology company reported a wider-than-expected third-quarter loss, reflecting increased operating expenses associated with personnel, clinical development and preparations for a potential regulatory submission. The company reported a net loss of $42.3 million for the three months ended September 30, 2026, compared…
-

Why Did Kolibri Global Energy’s Third-Quarter Revenue Rise 22% Despite Lower Production?
Kolibri Global Energy Inc. (NASDAQ:KGEI) reported a 22% increase in third-quarter 2026 revenue net of royalties to $18.3 million, compared with $15.0 million in the corresponding period of 2025, as higher realised commodity prices offset a decline in oil and gas production. The energy company reported a 34% increase in average realised prices during the…